

1 **Efficacy and safety of dihydroartemisinin-piperaquine for the treatment of**
2 **uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* malaria in Northern**
3 **Papua and Jambi, Indonesia**

4 Puji BS Asih¹, Ismail E Rozi¹, Farahana K Dewayanti¹, Suradi Wangsamuda¹, Syarifah
5 Zulfah², Marthen Robaha³, Jonny Hutahaean³, Nancy D Anggraeni⁴, Marti Kusumaningsih⁴,
6 Pranti S Mulyani⁴, Elvieda Sariwati⁴, Herdiana H Basri⁵, Maria Dorina G Bustos⁵, and Din
7 Syafruddin^{1,6}

8
9 ¹Malaria and Vector Resistance Unit, Eijkman Institute for Molecular Biology, Jakarta,

10 Indonesia

11 ²Jambi Provincial Health Department, Jambi Province, Indonesia

12 ³Papua Provincial Health Department, Papua Province, Indonesia

13 ⁴Malaria Sub Directorate, Ministry of Health, Republic of Indonesia

14 ⁵World Health Organization

15 ⁶Department of Parasitology, Faculty of Medicine, University of Hasanuddin, Makassar,

16 Indonesia

17

18 Din Syafruddin = <https://orcid.org/0000-0001-7141-2545>

19 Puji Budi Setia Asih = <https://orcid.org/0000-0002-4582-9133>

20

21 Dr. Din Syafruddin,

22 Eijkman Institute for Molecular Biology, Jakarta, Indonesia.

23 Tel +62-21-3917131, Fax +62-21-3147982

- 24 Puji BS Asih, puji@eijkman.go.id
- 25 Ismail E Rozi, eko@eijkman.go.id
- 26 Suradi Wangamuda, suradi@eijkman.go.id
- 27 Farahana K Dewayanti, farahanakd@eijkman.go.id
- 28 Syarifah Zulfah, zulfahsyarifah@yahoo.com
- 29 Marthen Robaha, robaha.marthen@yahoo.com
- 30 Jonny Hutahaeen, jonny.hutahaeen@yahoo.com
- 31 Nancy D Anggraeni, anancydian@gmail.com
- 32 Marti Kusumaningsih, kusumaningsihmarti@gmail.com
- 33 Pranti Sri Mulyani, pranti68@yahoo.com
- 34 Elvieda Sariwati, vielang@yahoo.com
- 35 Herdiana H Basri, basrih@who.int
- 36 Maria Dorina G Bustos, bustosm@who.int
- 37 Din Syafruddin, din@eijkman.go.id

38 **ABSTRACT** Dihydroartemisinin-piperaquine (DHA-PPQ) has been adopted as first-line
39 therapy for uncomplicated falciparum malaria in Indonesia since 2010. The efficacy of
40 DHA-PPQ was evaluated in 2 sentinel sites in Keerom District, Papua and Merangin
41 District, Jambi Provinces from April 2017 to April 2018. Clinical and parasitological
42 parameters were monitored over a 42-day period following the WHO standard *in vivo*
43 protocol and subjects meeting the inclusion criteria were treated with DHA-PPQ once daily
44 for 3 days, administered orally. In Keerom District, 6339 subjects were screened through
45 active and passive cases detection. A total of 114 subjects infected by *P. falciparum* and 83
46 subjects infected by *P. vivax* agreed to take a part through written informed consent. Kaplan-
47 Meier analysis of microscopy readings and PCR-corrected falciparum cases revealed a 93.1%
48 (95%CI:86.4-97.2) and 97.9% (95%CI:92.7-99.7) DHA-PPQ efficacy, respectively and were
49 classified as Adequate Clinical Parasitological Responses (ACPRs). For vivax malaria, the
50 DHA-PPQ efficacy were 89% (95%CI: 80.2 – 94.9) and 100% (95%CI: 95.1-100)
51 respectively. In Merangin District, 751 subjects were screened and 41 subjects infected by *P.*
52 *vivax* were recruited. Microscopy reading and PCR-corrected analysis revealed a 97.4%
53 (95%CI:86.2-99.9) and 100% (95%CI: 90.5-100) DHA-PPQ efficacy, respectively. No
54 severe adverse events were found in both sites. In both sites, there was no delay in parasite
55 clearance and no mutations in the PfK13 and PvK12 genes. Of the 6 recurrent *P. falciparum*
56 found, 2 indicated recrudescence and 4 cases were re-infection. Analysis of the PfPM2 gene at
57 day 0 and day of recurrence in recrudescence cases revealed the same single copy number,
58 whereas 3 of the 4 re-infection cases carried 2-3 copy numbers. In conclusion, treatment of
59 falciparum and vivax malaria cases with DHA-PPQ showed a high efficacy and safety. DHA-
60 PPQ regimen is also efficacious against *P. vivax* cases in the absence of primaquine.
61 **Keywords:** Therapeutic efficacy, Dihydroartemisinin-piperaquine (DHA-PPQ), *P.*
62 *falciparum* and *P. vivax*, Indonesia

63 Author Summary

64 This study aims to determine the efficacy and safety of dihydroartemisinin-piperaquine
65 (DHA-PPQ) to treat malaria patients in Indonesia. The study was conducted in 2 sites,
66 Keerom, Papua and Merangin, Jambi Provinces. In Keerom District, a total of 114 *P.*
67 *falciparum*-infected and 83 *P. vivax*-infected were recruited, treated under supervision with
68 DHA-PPQ once daily for 3 days. Kaplan-Meier analysis of microscopy readings and PCR-
69 corrected falciparum cases revealed a 93.1% and 97.9% efficacy, respectively and were
70 classified as Adequate Clinical Parasitological Responses (ACPRs). For vivax malaria, the
71 DHA-PPQ efficacy were 89% and 100%. In Merangin District, 751 subjects were screened
72 and 41 subjects were recruited. Microscopy reading and PCR-corrected analysis revealed a
73 97.4% and 100% efficacy. No severe adverse events were found in both sites. No delay in
74 parasite clearance was found and no mutations observed in the PfK13 and PvK12 genes. Of
75 the 6 recurrent *P. falciparum* found, 2 indicated recrudescence and 4 cases were re-infection.
76 Analysis of the PfPM2 gene at day 0 and day of recurrence in recrudescence cases revealed the
77 same single copy number, whereas 3 of the 4 re-infection cases carried 2-3 copy numbers.
78 Treatment of falciparum and vivax malaria cases with DHA-PPQ showed a high efficacy and
79 safety.

80 **Introduction**

81 In Indonesia, reports to date revealed that Artemisinin Combination Therapies
82 (ACTs), particularly dihydroartemisinin-piperaquine (DHA-PPQ) are still highly effective to
83 treat any human malaria cases. Although certain studies reported few cases of delayed
84 parasite clearance [1], this evidence was not linked to the artemisinin resistance. Subsequent
85 analysis on the cases revealed that the delay may be related to the higher parasite load as the
86 parasite is eventually eliminated by day 7. Therefore, routine monitoring of the therapeutic
87 efficacy of ACTs is essential for making timely changes of treatment policy. It can also help
88 to detect early changes in the parasite susceptibility to antimalarial drugs [2].

89 Malaria control program in Indonesia has successfully brought down the malaria cases
90 within the last few decades and in 2017, more than half of the district and municipality have
91 been certified as malaria free areas. However, malaria cases remain high in eastern
92 provinces, such as Papua, West Papua, Molucca and East Nusa Tenggara. In Western part of
93 the country, malaria is either eliminated or significantly reduced and only several malaria foci
94 left in Sumatra, Java, Bali and Kalimantan. In 2017 Indonesia reported 261,000 malaria
95 cases with 74% of infections reported from Papua Province [3]. Malaria problem in Indonesia
96 represents a unique archipelago setting that is entirely different with that of Africa. Malaria
97 control program relies on three pillars such as early diagnosis and prompt treatment,
98 provision of LLIN and indoor residual spraying (IRS) [4]. Unfortunately, the health care
99 facilities in remote setting where malaria is highly endemic does not always meet the
100 requirement to provide necessary service to the people. The absence of microscopists and
101 vector control officers reduce the effectiveness of the pillar and also provision of diagnosis
102 and prompt treatment. To avoid the unnecessary antimalarial drug deployment, the Ministry
103 of Health has set a treatment guideline in which antimalarial drug will only be given to
104 laboratory confirmed cases, either by microscopy or rapid diagnostic test (RDT). In

105 Indonesia, follow up of the malaria treatment is rarely done and therefore supervisory
106 treatment has been recommended to ensure that the patients indeed consumed the antimalarial
107 as prescribed. Since 2010, Indonesia recommended DHA-PPQ as first line drug for
108 uncomplicated malaria [5]. This includes all species of human malaria. The side-effects of
109 DHA-PPQ are abdominal pain, asthenia, cough, diarrhea, dizziness, fever, headache, joint
110 and muscle pain, loss of appetite, rash, nausea, vomiting. abdominal discomfort, nausea,
111 headache and dizziness. The objective of this study is to assess the therapeutic efficacy and
112 safety of DHA-PPQ for the treatment of uncomplicated *P. falciparum* and *P. vivax* malaria in
113 Indonesia.

114

115 **Methods**

116

117 **Ethics statement**

118 This study was approved by the Ethics Committee of Research in Health, Medical Faculty of
119 Hasanuddin University, Makassar, Indonesia (No. 663/H4.8.4.5.31/PP36-KOMETIK/2016
120 and No. 356/H4.8.4.5.31/PP36-KOMETIK/2017). The trial was registered with the clinical
121 trial number ACTRN12616001533482.

122

123 **Study Site**

124 The study was conducted in Keerom District and Merangin District from April 2017 – April
125 2018. The location of the Keerom District in Papua and Merangin District in Jambi
126 Provinces within Indonesia archipelago is shown in Figure 1. The climate is typically tropical
127 in both sites. In Merangin District, Jambi Province the rainy season occurs from December to
128 April, whereas in Keerom District rainy and dry season could not be separated clearly as the

129 rainfall occurred throughout the year. The average temperatures are 18–20°C during the
130 cooler rainy months from December to April and 25–33°C during the dry season.

131

132 ***In vivo* drug efficacy study**

133 Participants were recruited from among malaria-infected persons found during active
134 malariometric surveys (active case detection (ACD)) or from persons attending outpatient
135 clinics at Primary Health Centres (passive case detection (PCD)) in Keerom District and
136 Merangin District. Persons were eligible to enrol in the study if they were aged between 1 –
137 65 years, weighed more than 5 kgs, had fever or history of fever in the preceding 24 hours,
138 with slide-confirmed malaria with parasitemia of more than 500/ul asexual parasites for *P.*
139 *falciparum* and more than 250/ul asexual parasites for *P. vivax*. Persons were excluded if they
140 met any of the following exclusion criteria: 1) were pregnant, 2) had a history of allergy to
141 the study drugs or study drug's derivative, 3) had previously completed treatment with an
142 antimalarial drug in the preceding two weeks, or 4) had a medical history of untreated
143 hypertension or chronic heart, kidney, or liver disease [6].

144

145 **Laboratory procedures**

146 Before enrolment, a finger prick was performed to obtain blood to prepare thick and thin
147 blood smears and blots on filter paper (Whatman International Ltd., Maidstone, United
148 Kingdom), for parasite genotyping, and for hemoglobin measurements (HemoCue™
149 Hb201+; HemoCue, Angelholm, Sweden). Smears and filter paper blood samples were also
150 collected from finger pricks on days 1, 2, 3, 7, 14, 21, 28, 35 and 42 [6, 7]. Smears were read
151 by expert microscopists and confirmed by polymerase chain reaction (PCR). Any discordant
152 results between microscopy and PCR were resolved by independent PCR confirmation. All
153 study participants had the G6PD level checked using Care start Rapid G6PD deficiency

154 whole blood test.

155

156 **Antimalarial therapy**

157 All study participants were given a supervised treatment of dihydroartemisinin (DHA) and
158 piperazine (PPQ), containing 40 mg DHA and 320 mg PPQ per tablet and was administered
159 once a day for 3 days, as a weight per dose regimen of 2.25 and 18 mg/kg of DHA-PPQ [8]
160 and followed-up weekly for 42 days. A study nurse distributed the drugs, observed and
161 recorded all treatments, and repeated the treatment if vomiting occurred within 30 minutes
162 following the drug administration. Parasitological responses were classified according to
163 criteria of the World Health Organization [9]. Adverse events observed during the study were
164 recorded by the study nurse and/or physician. Primaquine therapy was not provided until
165 discontinuation from the study i.e., day of recurrence or day 42.

166

167 **Parasitological analysis**

168 Thick and thin blood smears were stained with Giemsa and subsequently examined in light
169 microscopy. Parasitemia was determined with parasite counted per 200 white blood cells in
170 follow-up smears, counting will be done against at least 500 white blood cells. A blood slide
171 will be considered negative when examination of 1000 white blood cells or 100 fields
172 containing at least 10 white blood cells per field reveals no asexual parasites. All slides were
173 read by a certified microscopist and cross-checked by a second experienced microscopist. In
174 cases where readings were discordant, the slides were reread by third microscopist and a
175 consensus reached.

176

177 **Preparation of genomic DNA**

178 Parasite and human host DNA (on day of enrolment and day of recrudescence) was extracted
179 from blood samples using Chelex-100 ion exchanger (Bio-Rad Laboratories, Hercules, CA)
180 according to a previously published procedure [10]. Extracted DNA was either used
181 immediately for Polymerase Chain Reaction (PCR) assays or stored at -20°C for later
182 analysis.

183

184 **PCR Correction**

185 Plasmodium was identified using microscopic test, which was followed by an evaluation
186 using PCR. The PCR involved five primer sets. In the first amplification reaction (Nested 1),
187 a pair of primers with genus specific of rPLU1 and rPLU5 was used and a total of 25 μl
188 volume was used for all reactions. Furthermore, primers for the second amplification
189 reaction (Nested 2) were used following the procedure described previously [11]. Data
190 obtained from microscopy reading and PCR correction were calculated using Kaplan-Meier
191 analysis.

192

193 **Genotyping and PCR amplification of *P. falciparum* and *P. vivax* genes**

194 Genotyping using the genes for merozoite surface protein 1(MSP1), MSP2, and glutamate-
195 rich protein (GLURP) was performed in certain participants to distinguish between pre-
196 treatment and recrudescence parasites [12]. Amplifications of Pf K13 and Pv K12 genes for
197 artemisinin resistance were performed according to previously published. The DNA was
198 amplified by nested PCR and sequencing method to detect the mutations G449A, N458Y,
199 T474I; M476I; A481V; Y493H; T508N; P527T; G533S; N537I; R539T; I543T; P553L;
200 R561H; V568G; P574L; C580Y of *P. falciparum* K13 [13 - 17]. Identification of 8
201 nonsynonymous K12 mutations at codons M448, T517, F519, I568, S578, D605, D691, L708
202 for K12 of *P. vivax* K12 [18].

203

204 **Quantitative PCR to assess *P. falciparum* plasmepsin 2 gene copy number**

205 Copy number of *P.falciparum* plasmepsin 2 gene determination consisted of several stages.

206 Initially, DNA was extracted from the blood spots on filter paper according to the Wooden

207 method [10] and purified using Qiagen Kit. The DNA extract were then used as templates in

208 the amplification process of the copy number gene target *PfPM2* and *Pftub* genes using

209 quantification of the real time polymerase chain reaction (RT-qPCR) and assay parameters

210 according to the Witkowski method. The primers used for *PfPM2* gene were 5'-

211 TGGTGATGCAGAAGTTGGAG -3' and 5'-TGGGACCCATAAATTAGCAGA -3', while

212 for *Pftubulin* these were 5'-TGATGTGCGCAAGTGATCC -3' and 5'-

213 TCCTTTGTGGACATTCTTCCTC -3' [19]. Each control and samples were quantified in

214 triplicates for *PfPM2* and *Pftub*. The 3D7 strain were quantified in 6 replicates for *PfPM2* and

215 *Pftub*. Interpretation of results and run validation followed the Witkowski method. The 3D7

216 strain line was included in each run as standard control for one copy of *PfPM2* gene in 6

217 replicates. *PfPM2* copy number was calculated by the $2^{-\Delta\Delta C_t}$ method [19] and the value was

218 rounded up.

219

220 **RESULTS**

221

222 **Keerom District, Papua**

223 Of the 6339 subjects screened through passive and active case detections (Fig 2), 1984

224 (31.3%) were found positive for malaria. *Falciparum* malaria dominated the malaria cases

225 (56%, 1112/1984) and followed by vivax malaria at 37.8% (749/1984). An additional 3.4%

226 (68/1984) were positive for *Plasmodium malariae*; 1 (0.05%) had *Plasmodium ovale*; 42

227 (2.1%) had mixed infections of *P. falciparum* and *P. vivax*, *P. falciparum* and *P. ovale* 1

228 (0.05%), 1 (0.05%) *P. vivax* and *P. malariae* (Fig 2 - 3).

229

230 A total of 114 (5.7%) of the 1984 *P. falciparum* cases and 83 (4.2%) *P. vivax* cases met
231 inclusion criteria (Table 1; Fig 2 - 3). The remaining subjects were excluded due to age,
232 inadequate asexual parasitemia, unplanned travelling, refusal to provide consent, and local
233 tribes war (unsecure situation for follow up activity).

234

235 Table 1 lists the demographic characteristics of the study subjects at enrolment. Of the 114
236 enrolled subjects for falciparum cases, 56 were males and 58 were females with age ranging
237 from 1 to 65 years (mean 22 years). At enrolment, the density of asexual forms ranged from
238 600 to 213000 per µl blood, whereas sexual stages (gametocytes) were found in 5 subjects
239 (4.4%) (Table 7). During the follow up, gametocytes were found in few cases (Table 4-5).

240

241 **Clinical and parasitological efficacy of DHA-PPQ for falciparum cases in Keerom,**

242 **Papua**

243 Classification of the treatment outcomes (microscopy and PCR corrected) for falciparum
244 cases is presented in Table 2. At day 42, ACPR was noted in 93.1% by microscopy and PCR
245 correction. No patients showed ETF, while LCF was reported in 1 study participant. LPF
246 was observed in 6 study participants with PCR correction. Withdrawn or drop out was
247 observed in 1 case (0.9%). Lost to followed up was observed in 11 study participants. Of the
248 114 falciparum cases enrolled, 112 cases were successfully cleared at day 2. The remaining 2
249 cases were cleared at day 3. No delayed parasite clearance was observed. Recurrent parasites
250 were detected in 6 cases, at days 21, 35 and day 42 (Table 6).

251

252 **Differentiation of recrudescence with reinfection**

253 Genotypic analyses of the parasites at day 0 and day of recurrence were conducted using the
254 3-markers recommended by WHO; *msp1*, *msp2*, and *glurp* genes as shown in Table 6. Of the
255 6 LPF cases, 4 cases were categorized as re-infection as the genotypes of the parasites found
256 at day of recurrence were different with that of day 0 (pre-treatment). The remaining 2
257 subjects showed the same genotypes for the 3 markers and therefore could be determined as
258 either recurrence or re-infection. Nonetheless, either case indicate resistance as they have
259 survived the challenge of sub-curative dose of piperaquine

260

261 **Determination of the existence of SNPs in the Pfk13**

262 PCR amplification and DNA sequencing of the Pf K13 gene to observe the 20 SNPs
263 associated with Artemisinin resistance; G449A, N458Y, T474I; M476I; A481V; Y493H;
264 T508N; P527T; G533S; N537I; R539T; I543T; P553L; R561H; V568G; P574L; C580Y
265 revealed that all *P. falciparum* isolates carried the wildtype allele.

266

267 ***Plasmodium falciparum* plasmepsin 2 gene copy number**

268 Late parasitological failure (LPF) was observed in 6 study participants with microscopy
269 reading (Table 2). The delta Ct from 6 LPF were compare with Ct from control, *P.*
270 *falciparum* strain 3D7. The estimation of the copy number from 6 LPF was calculated (Table
271 7). Three LPF (PAF 01, 08, and 19) had the same copy number of plasmepsin 2 in day 0 and
272 day recurrence. Two LPF (PAF 37 and 112) have increased 2 copy number of plasmepsin 2
273 in day 0 and day recurrence, while 1 LPF (PAF 133) had copy number 3. Of the 6 recurrent
274 *P. falciparum* found, 2 indicated recrudescence and 4 cases were re-infections (Table 9).
275 Analysis of the PfPM2 gene at day 0 and day of recurrence in recrudescence cases (PAF 01
276 and 19) revealed the same single copy number, whereas 3 of the 4 re-infection cases carried
277 2-3 copy numbers (Table 7).

278

279 **Clinical and parasitological efficacy of DHP for vivax cases in Keerom, Papua**

280 Table 3 lists the demographic characteristics of the study subject at enrolment. Of the 83
281 enrolled subjects for vivax cases, 42 were males and 41 were females with age ranging from
282 2 to 45 years (mean 15 years) (Table 1). At enrolment, the density of asexual forms ranged
283 from 40 to 31800 μ l, whereas the sexual stages (gametocytes) were found in 15 subjects
284 (18.1%) (Table 8). At follow up, gametocytes were only found in 3 cases; 1 in day 2, 1 in day
285 3 and 1 in day 42 (Table 5). Classification of the treatment outcomes (microscopy and PCR
286 corrected) for vivax cases is presented in Table 6. At day 42 an ACPR was noted in 89% by
287 microscopy and 100% after PCR correction. No patients showed ETF for vivax cases, while
288 LCF was reported in 1.2%. LPF was observed in 8 study participants without PCR
289 correction. Lost to followed up was observed in 1 study participant (Table 3). Of the 83 vivax
290 cases enrolled, no delayed parasite clearance was observed.

291

292 **Merangin District, Jambi Province**

293 Of the 751 subjects screened through passive and active case detection, 50 (66.7%) were
294 found positive for malaria. Only vivax malaria cases were found (Fig 4). A total of 41 (82%)
295 *P. vivax* cases met inclusion criteria. The remaining subjects were excluded due to age,
296 inadequate asexual parasitemia, and refusal to provide consent. The demographic
297 characteristics of the study subject at enrolment is shown in Table 1. Of the 41 enrolled
298 subjects for vivax cases, 19 were males and 22 were females with age ranging from 2 to 58
299 years (mean 16 years). At enrolment, the density of asexual forms ranged from 40 to 9320 μ l,
300 whereas sexual stages (gametocytes) were found in 18 subjects (43.9%) (Table 5).

301

302 **Clinical and parasitological efficacy of DHP for vivax cases in Merangin, Jambi**

303 Classification of the treatment outcomes (microscopy and PCR corrected) for vivax cases is
304 presented in Table 3. At day 42, ACPR was noted in 97.4% of the cases by microscopy and
305 100% after PCR correction. No patients showed ETF and LCF for vivax cases, while LPF
306 was reported in 2.6%. LPF was observed in 1 study participant without PCR correction. One
307 study participant was withdrawn due to unscheduled traveling. Lost to followed up was
308 observed in 2 study participants (Table 3). No gametocyte was found after the treatment
309 completed and during the follow up period up to day 42 except for 1 case where gametocyte
310 appeared at day 35.

311

312 **Determination of the existence of SNPs in the PvK12**

313 PCR amplification and DNA sequencing of the Pv K12 gene to observe the 8 SNPs
314 associated with Artemisinin resistance; M448, T517, F519, I568, S578, D605, D691, L708
315 revealed that all *P. vivax* isolates carried the wildtype allele for samples from Keerom
316 District and Merangin District.

317

318 **Evaluation of the adverse event**

319 No adverse event was reported during the follow up of this study in Keerom (Papua) and
320 Merangin (Jambi).

321

322 **Gametocyte carriage during the treatment**

323 Gametocytemia was present at enrolment in 5 patients in Keerom District (Papua) infected
324 with *P. falciparum* and 15 patients with *P. vivax* malaria while 18 patients had gametocyte
325 carriage at day of enrollment in Merangin District (Jambi) (Table 5). The proportion of
326 patients with patent gametocytemia in those with *P. falciparum* infection was 4.4% at D0,
327 1.7% at D2, 1,7% at D3, and 2.6% at D7. In Keerom patients with *P. vivax* malaria, the

328 proportion with gametocyte fell from 18.1% at D0 to 1.2% at D2, D3 and D42, while in
329 Merangin District (Jambi) the proportion of patients with patent gametocytemia in those with
330 *P. vivax* infection was 43.9% at D0 and 2.4% at D35 (Table 5).

331

332 **Discussion**

333 Development and spread of the parasite resistance to the currently available artemisinin-
334 based combination therapy (ACT) poses a substantial threat to the currently endorsed malaria
335 elimination program as it may increase not only malaria morbidity but also re-introduction of
336 malaria in areas where elimination have been achieved. Results of this study clearly indicate
337 that DHA-PPQ is still highly effective in both study sites. Nevertheless, in Keerom District
338 Papua, evidence for the existence of parasite isolates that are resistant to PPQ alerts to the
339 proper deployment of the drug in the area. Piperaquine resistance is associated with the
340 increased copy number of the plasmepsin gene [19, 20] and as a result the treatment failed to
341 completely eliminate the parasite from the blood or prevent reinfection during the follow up
342 period. This study found the presence of 2 recrudescence cases at days 21 and 35 and re-
343 infection at days 35-42 (Table 6). Recrudescence and re-infection following treatment with
344 DHP were associated with higher prevalence of Kelch13 mutations, higher piperaquine 50%
345 inhibitory concentration (IC50) values, and lower mefloquine IC50 values [19 - 23]. The
346 high gametocyte carriage at enrolment in vivax cases (~43.9%) in this study (Table 5) is
347 likely associated with the poor accessibility to treatment and also compliance to the treatment
348 regimen. Almost 50% of the subjects had received previous DHA-PPQ but never completed
349 the 14 day primaquine treatment as recommended. This situation requires attention as it may
350 expedite parasite resistance to the DHA-PPQ as well as support for local transmission. In
351 Papua the efficacy of DHA-PPQ against *P. falciparum* and *P. vivax* were 97.9% and 100%
352 respectively, with 6 recurrent infections for falciparum malaria. However, the proportion of

353 parasitemic patients fell rapidly and none of the patients were parasitemic at day 3. This
354 findings indicate that artemisinin is still highly effective but caution has to be given to the
355 partner drug, piperaquine. The results of the molecular analysis also support the finding as
356 none of the parasites had the polymorphisms in the K13 and K12 gene that have previously
357 been associated with artemisinin resistance. However, of the 6 recurrent parasites, 3 carried
358 the amplification of the *plasmepsin 2–3* gene cluster. The evidence for DHA-PPQ late
359 treatment failure in this study alerts to the proper treatment of malaria in the area and also
360 anticipate having second line ACT to replace the piperaquine partner drug. Currently, the
361 Indonesia national policy to use quinine as second line drug is regarded to be impractical as it
362 introduces longer treatment period and also more often side effect. In this regard,
363 consideration of using another ACT such as Arthemeter+lumefantrine or
364 Artesunate+mefloquine at least for falciparum cases might be rational. The results from this
365 study are reassuring and suggest that in the absence of artemisinin resistance, the ACT
366 regimen may delay de novo emergence of resistance to the partner drug. DHA-PPQ has been
367 used in Indonesia as the first line antimalarial drug since 2008 [24] and it took almost 10
368 years to first detect the early sign of resistance to the partner drug, piperaquine. In
369 Cambodia, amplification of the *plasmepsin 2–3* gene cluster has been identified as an
370 important molecular determinant of piperaquine resistance in *P. falciparum* [21 - 23] and
371 resistance to piperaquine in fact increase the sensitivity of the mefloquine [19]. This
372 phenomenon may complement for the replacement of piperaquine as partner drug of
373 artemisinin in the area if the resistance is spread. In Indonesia, DHA-PPQ procurement is
374 highly regulated by the Indonesian Ministry of Health, and the drug is only available at
375 government health facilities and selected private-sector facilities, which are able to confirm
376 that the prescription should be based on malaria positivity by microscopy or rapid diagnostic
377 test. With this tight regulation it is anticipated that DHA-PPQ will continue to play a role in

378 the treatment of uncomplicated malaria in Indonesia until malaria is successfully eliminated
379 in the country. On another aspect, implementation of evidence-based vector control may also
380 contribute to mitigate transmission and delay the emergence of antimalarial drug resistance.

381

382 **Conclusions**

383 The therapeutic efficacy study conducted in two sentinel sites in Papua and Jambi,
384 Indonesia during 2017-2018 revealed that DHA-PPQ is still highly effective in both
385 sites. The appearance of recurrent falciparum infection in small number of cases in
386 Papua alert to the possible emergence of piperaquine resistance in the area and deserve
387 further investigation to contain its spread and anticipate for the rational option of a
388 second line ACT. Further study is required in different regencies in Papua, particularly
389 those in border area with Papua New Guinea to determine the spread of resistance to
390 DHA-PPQ.

391

392 **Acknowledgments**

393 The authors are grateful to participants in this study. The authors are deeply grateful to
394 Chairman of the Eijkman Institute for Molecular Biology (EIMB), Professor Amin
395 Soebandrio MD., Ph.D., Clin. Microbiol and Coordinator Director Office Global Malaria
396 Programme WHO, Dr. Pascal Ringwald for their support and encouragement in this activity.
397 The authors wish to thank Ahmad N Azhari from WHO, staffs from Papua and Jambi
398 Provincial Health Departments, Keerom and Merangin District Health Departments and
399 Primary Health Centers at study sites for the support, encouragement and helping for samples
400 collection. We thank Nadha Rizky Pratama, Sylvia Sance Marantina, Jenifer Kiem Aviani,
401 and Annisa Rizkia for their assistance in the EIMB laboratory.

402

403 **Data availability statement**

404 All relevant data are within the manuscript

405

406 **Author Contribution**

407 Conceptualization: Maria Dorina G Bustos, Din Syafruddin

408 Data curation: Puji BS Asih, Ismail E Rozi, Farahana K Dewayanti, Suradi Wangsamuda,

409 Syarifah Zulfah, Marthen Robaha, Jonny Hutahaean, Nancy D Anggraeni, Marti

410 Kusumaningsih, Pranti S Mulyani, Elvieda Sariwati, Herdiana H Basri,

411 Formal analysis: Puji BS Asih, Ismail E Rozi, Farahana K Dewayanti, Suradi Wangsamuda,

412 Maria Dorina G Bustos, Din Syafruddin

413 Funding acquisitions: Maria Dorina G Bustos, Din Syafruddin

414 Investigation: Puji BS Asih, Ismail E Rozi, Farahana K Dewayanti, Suradi Wangsamuda,

415 Maria Dorina G Bustos, Din Syafruddin

416 Methodology: Puji BS Asih, Ismail E Rozi, Farahana K Dewayanti, Maria Dorina G Bustos,

417 Din Syafruddin

418 Project administration: Puji BS Asih, Syarifah Zulfah, Marthen Robaha, Din Syafruddin

419 Supervision: Marti Kusumaningsih, Pranti S Mulyani, Syarifah Zulfah, Marthen Robaha,

420 Maria Dorina G Bustos, Din Syafruddin

421 Writing – original draft: Puji BS Asih, Din Syafruddin

422 Writing – review & editing: Puji BS Asih, Ismail E Rozi, Farahana K Dewayanti, Suradi

423 Wangsamuda, Syarifah Zulfah, Marthen Robaha, Jonny Hutahaean, Nancy D Anggraeni,

424 Marti Kusumaningsih, Pranti S Mulyani, Elvieda Sariwati, Herdiana H Basri, Maria Dorina G

425 Bustos, Din Syafruddin

426

427 **References**

428

- 429 1. Asih PBS, RM Dewi, S Tuti, M Sadikin, W Sumarto, B Sinaga, et al. Efficacy of
430 Artemisinin-Based Combination Therapy for Treatment of Persons with
431 Uncomplicated *Plasmodium falciparum* Malaria in West Sumba District, East Nusa
432 Tenggara Province, Indonesia, and Genotypic Profiles of the Parasite. *Am J Trop Med*
433 *Hyg.* 2009;80:16:914 – 18. <https://doi.org/10.4269/ajtmh.2009.80.914>
- 434 2. WHO. Methods for Surveillance of Antimalarial Drug Efficacy. 2009. Available at:
435 http://apps.who.int/iris/bitstream/10665/44048/1/9789241597531_eng.pdf
- 436 3. Ministry of Health, Republic of Indonesia. Buku saku pedoman pengobatan malaria di
437 Indonesia. 2017. Available at
438 https://drive.google.com/file/d/0BxNNPzsAPw_gbVpuX2NPY3g5eVE/view
- 439 4. WHO. Global Technical Strategy For Malaria 2016–2030. 2015. Available at
440 https://apps.who.int/iris/bitstream/handle/10665/176712/9789241564991_eng.pdf;jsessionid=6A0E113E5A0C1AC4C850D6239E467005?sequence=1
- 442 5. Ministry of Health, Republic of Indonesia. Buku saku pedoman pengobatan malaria di
443 Indonesia. 2010.
- 444 6. WHO. Methods And Techniques For Clinical Trials On Antimalarial Drug Efficacy:
445 genotyping to identify parasite populations. 2007. Available at
446 https://apps.who.int/iris/bitstream/handle/10665/43824/9789241596305_eng.pdf?sequence=1&isAllowed=y
- 448 7. Flegg JA, Guerin PJ, White NJ, Stepniewska K, 2011. Standardizing the measurement
449 of parasite clearance in falciparum malaria: the parasite clearance estimator. *Malar J.*
450 2011;10: 339. *Malar J.* 2011;10:10:339. doi: 10.1186/1475-2875-10-339.
- 451 8. Ministry of Health, Republic of Indonesia. The National Guideline for Malaria
452 Treatment in Indonesia. 2013.

- 453 9. WHO. Monitoring antimalarial drug resistance, Report of a WHO consultation.
454 Geneva, Switzerland. 2002. Available at
455 [https://apps.who.int/iris/bitstream/handle/10665/67590/WHO_CDS_CSR_EPH_2002.](https://apps.who.int/iris/bitstream/handle/10665/67590/WHO_CDS_CSR_EPH_2002.17.pdf?sequence=1&isAllowed=y)
456 [17.pdf?sequence=1&isAllowed=y](https://apps.who.int/iris/bitstream/handle/10665/67590/WHO_CDS_CSR_EPH_2002.17.pdf?sequence=1&isAllowed=y)
- 457 10. Wooden J, Kyes S, Sibley CH. PCR and strain identification in *Plasmodium*
458 *falciparum*. Parasitol Today, 1993;9:303-5. doi:10.1016/0169-4758(93)90131-x.
459 PMID: 15463789
- 460 11. Singh B, Bobogare A, Cox-Singh J, Snounou G, Abdullah MS, Rahman HA, 1999. A
461 genus- and species-specific nested polymerase chain reaction malaria detection assay
462 for epidemiologic studies. Am J Trop Med Hyg 60: 687–92. doi:
463 10.4269/ajtmh.1999.60.687. PMID: 10348249
- 464 12. Methods in Malaria Research: Genotyping of *Plasmodium falciparum* parasites by
465 PCR: msp1, msp2, and glurp, by Georges Snounou and Anna Färnert. ed. Inger
466 Ljungström, Hedvig Perlmann, Martha Schlichtherle, Artur Scherf, Mats Wahlgren. 4.
467 ed. Malaria Research and Reference Reagent Resource Center (MR4), 2008;p.221-25.
- 468 13. Dondorp AM, Nosten F, Yi P, Das D, Phyto AP, Tarning J, et al. Artemisinin
469 resistance in *Plasmodium falciparum* malaria. N Engl J Med. 2009;361: 455–67. doi:
470 10.1056/NEJMoa0808859.
- 471 14. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of
472 artemisinin resistance in *Plasmodium falciparum* malaria. N Engl J Med. 2014;371:
473 411–23. DOI: 10.1056/NEJMoa1314981. PMID: 25075834.
- 474 15. Phyto AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, et al.
475 Emergence of artemisinin-resistant malaria on the western border of Thailand: a
476 longitudinal study. Lancet. 2012;379:1960–66. doi: 10.1016/S0140-6736(12)60484-
477 X. PMID: 22484134.

- 478 16. Tun KM, Imwong M, Lwin KM, Win AA, Hlaing TM, Hlaing T, et al. Spread of
479 artemisinin-resistant *Plasmodium falciparum* in Myanmar: a cross-sectional survey of
480 the K13 molecular marker. *Lancet Infect Dis* 2015;15: 415–21. doi: 10.1016/S1473-
481 3099(15)70032-0. PMID: 25704894
- 482 17. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM. Evidence of
483 artemisinin-resistant malaria in western Cambodia. *N Engl J Med*. 2008;359: 2619–
484 20. doi: 10.1056/NEJMc0805011. PMID: 19064625.
- 485 18. Popovici J, Kao S, Eal L, Bin S, Kim S, Ménard D. Reduced Polymorphism in the
486 Kelch Propeller Domain in *Plasmodium vivax* Isolates from Cambodia. *Antimicrob*
487 *Agents Chemother*. 2015;59(1): 730–3. doi: 10.1128/AAC.03908-14 . PMID:
488 25385109.
- 489 19. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et.al. A surrogate
490 marker of piperazine-resistant *Plasmodium falciparum* malaria: a phenotype-
491 genotype association study. *Lancet Infect Dis*. 2017;17: 174–83. doi: [10.1016/S1473-
492 3099\(16\)30415-7](https://doi.org/10.1016/S1473-3099(16)30415-7). PMID: [27818097](https://pubmed.ncbi.nlm.nih.gov/27818097/)
- 493 20. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperazine: a resurgent
494 antimalarial drug. *Drugs* 2005;65: 75–87. doi: 10.2165/00003495-200565010-00004 .
495 PMID: 15610051
- 496 21. Leang R, Barrette A, Bouth DM, Menard D, Abdur R, Duong S, et al. Efficacy of
497 dihydroartemisinin-piperazine for treatment of uncomplicated *Plasmodium*
498 *falciparum* and *Plasmodium vivax* in Cambodia, 2008 to 2010. *Antimicrob Agents*
499 *Chemother*. 2013;57: 818–826. doi: 10.1128/AAC.00686-12. PMID: 23208711.
- 500 22. Leang R, Taylor WRJ, Bouth DM, Song L, Tarning J, Char MC, et al. Evidence of
501 *Plasmodium falciparum* malaria multidrug resistance to artemisinin and piperazine
502 in western Cambodia: dihydroartemisinin-piperazine open-label multicenter clinical

- 503 assessment. *Antimicrob Agents Chemother* 59: 4719–26. doi: 10.1128/AAC.00835-
504 15 . PMID: 26014949
- 505 23. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, et al. Dihydroartemisinin-
506 piperaquine resistance in *Plasmodium falciparum* malaria in Cambodia: a multisite
507 prospective cohort study. *Lancet Infect Dis*. 2016;16: 357–65. DOI: 10.1016/S1473-
508 3099(15)00487-9 . PMID: 26774243.
- 509 24. Hasugian AR, Purba HLE, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R,
510 et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior
511 efficacy and posttreatment prophylaxis against multidrug-resistant *Plasmodium*
512 *falciparum* and *Plasmodium vivax* malaria. *Clin Infect Dis* 2007;15:44(8):1067-74.
513 doi: 10.1086/512677. PMID: 17366451
- 514

515 **Figure Legends:**

516

517 **Figure 1.** Figure 1. Study Sites in Papua and Jambi Provinces. Map from Natural Earth.

518 <https://www.naturalearthdata.com/>

519 **Figure 2.** Flow chart sample collection for falciparum cases in Keerom, Papua

520 **Figure 3.** Flow chart sample collection for vivax cases in Keerom, Papua

521 **Figure 4.** Flow chart sample collection for vivax cases in Merangin, Jambi

522

Table 1. Baseline characteristics of study participants

523

Variable	Overall cases		
	Papua		Jambi
	Falciparum	Vivax	Vivax
Number of patients enrolled (n)	114	83	41
Age (years)			
-Mean (SD)	22 (16.8)	15.1 (11.9)	16.6 (14)
-Range	1-65	2-45	2-58
Gender			
-Male [n (%)]	56 (49.1%)	42 (50.6%)	19 (46.3%)
-Female [n (%)]	58 (50.9%)	41 (49.4%)	22 (53.7%)
Body temperature [°C, mean (SD)]	37.6 (1.2)	37.4 (1.4)	36.8 (1.0)
-Range	35-39.9	35-40.3	36-41
Parasite density (/µl)	10777	3918	1512
[mean geometric parasitemia]			
-Range	600-213000	40-31800	40-9320

524

525 Table 2. Falciparum phenotyping result from Keerom, Papua
 526 during the 42 days of follow up

527

Study Site	Total Subject	Diagnosis by	Outcome (Number of patients)					
			ETF	LCF	LPF	ACPR	LTU	WTH
Papua	114	Microscopy	0	1 (1%)	6 (5.9%)	95 (93.1%) (95%CI:86.4-97.2) *	11	1
	114	PCR corrected	0	1 (1%)	1 (1%)	95 (97.9%) (95%CI:92.7-99.7)	11	6

528 ETF = Early treatment failure; LCP = Late clinical failure;
 529 LPF = Late parasitological failure; LTU = Lost to follow up; WTH = Withdrawn
 530 ACPR = Adequate clinical and parasitological response; (*) = Kaplan-Meier Analysis
 531

532 Table 3. Vivax phenotyping result from Keerom, Papua and Merangin, Jambi Provinces
 533 during the 42 days of follow up

534

Study Site	Total Subject	Diagnosis by	Outcome (Number of patients)					
			ETF	LCF	LPF	ACPR	LTU	WTH
Papua	83	Microscopy	0	1 (1.2%)	8 (9.8%)	73 (89%) (95%CI:80.2-94.9) *	1	0
	79	PCR corrected	0	0	0	73 (100%) (95%CI:95.1-100)	1	5
Jambi	41	Microscopy	0	0	1 (2.6%)	37 (97.4%) (95%CI:86.2-99.9)	2	1
	40	PCR corrected	0	0	0	37 (100%) (95%CI:90.5-100)	2	1

535 ETF = Early treatment failure; LCP = Late clinical failure;
 536 LPF = Late parasitological failure; LTU = Lost to follow up; WTH = Withdrawn
 537 ACPR = Adequate clinical and parasitological response; (*) = Kaplan-Meier Analysis
 538

Table 4. Gametocyte of *P. falciparum* appearance during the 42 days of follow up

Study Site	Total Sample	Days of follow-up									
		D0	D1	D2	D3	D7	D14	D21	D28	D35	D42
Papua	114	5 (4.4%)	-	2 (1.7%)	2 (1.7%)	3 (2.6%)	2 (1.7%)	1 (0.9%)	1 (0.9%)	0	0

(-) = No blood sample

Table 5. Gametocyte of *P. vivax* appearance during the 42 days of follow up

Study Site	Total Sample	Days of follow-up										
		D0	D1	D2	D3	D7	D14	D21	D28	D35	D42	
Papua	83	15 (18.1%)	-	1 (1.2%)	1 (1.2%)	0	0	0	0	0	0	1 (1.2%)
Jambi	41	18 (43.9%)	-	0	0	0	0	0	0	0	1 (2.4%)	0

(-) = no blood sample


Table 6. Genotyping results of the parasites
at day 0 and day recurrence in *P. falciparum* cases

Isolate Code	D0 Strain MSP1/MSP2/GLURP	DR Strain MSP1/MSP2/GLURP	Day of Recurrence	Recrudescence/Reinfection
PAF 01	K1/FC27/Code1*	K1/FC27/Code1	D21	Recrudescence/Reinfection
PAF 08	K1/FC27/Code2	K1-RO33/FC27/Code3	D42	Reinfection
PAF 19	K1/FC27/Code1	K1/FC27/Code1	D35	Recrudescence/Reinfection
PAF 37	K1/FC27/Code2	K1-RO33/FC27/Code3	D42	Reinfection
PAF 112	K1/FC27/Code3	MAD20/3D7/Code3	D42	Reinfection
PAF 133	K1/MAD20/FC27Code2	RO33/3D7/Code3	D35	Reinfection

(* , amplicon in GLURP): Code1= 501 – 600 base pairs (bp); Code2= 601 – 700 bp; and Code3 = 701 – 800 bp

Table 7. PfPM2 Gene Copy Number of the parasites
at day 0 and day recurrences in *P. falciparum* cases

Isolate Number	PfPM2 Copy Number		Day of Recurrence
	D0	DR Strain	
PAF 01	1	1	D21
PAF 08	1	1	D42
PAF 19	1	1	D35
PAF 37	1	2	D42
PAF 112	1	2	D42
PAF 133	1	3	D35



SUMATRA

BORNEO

CELEBES

PAPUA

JAVA

Merangin District
Jambi province
- *P vivax*

Jakarta

Denpasar

Keerom District
Papua Province
- *P falciparum*
- *P vivax*

